Pacira BioSciences (PCRX) Institutional Ownership

99.73% of Pacira BioSciences' stock is owned by institutional investors. Learn more on PCRX's institutional investor holdings.

Of the 212 institutional investors that purchased Pacira BioSciences' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Pacer Advisors Inc. ($3.39M), Doma Perpetual Capital Management LLC ($1.37M), Alyeska Investment Group L.P. ($1.31M), American Century Companies Inc. ($1.30M), Point72 Asset Management L.P. ($1.08M), Balyasny Asset Management L.P. ($999.49K), and Jacobs Levy Equity Management Inc. ($855.49K).

Institutional investors have bought a total of 7,856,315 shares in the last 24 months. This purchase volume represents approximately $196.04M in transactions.

Of the 100 institutional investors that sold Pacira BioSciences' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Russell Investments Group Ltd. ($5.75M), Balyasny Asset Management L.P. ($1.18M), Jacobs Levy Equity Management Inc. ($814.27K), Millennium Management LLC ($624.57K), Vanguard Group Inc. ($593.01K), UBS Group AG ($470.24K), and Assenagon Asset Management S.A. ($440.92K).

Institutional investors have sold a total of 13,270,798 shares in the last 24 months. This volume of shares sold represents approximately $329.53M in transactions.